Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials

Article Dermatology

Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials

A. Wollenberg et al.

Summary: Tralokinumab treatment for moderate-to-severe AD patients is associated with a higher incidence of conjunctivitis compared to placebo, but the majority of cases are mild and transient.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Allergy

IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro

Pernille M. Hansen et al.

ALLERGY (2022)

Add to Collection

Article Dermatology

Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis

Maria C. Schneeweiss et al.

Summary: In this population-based study on adult AD patients, cyclosporine and methotrexate had the lowest 6-month risks of serious infections, while increased risks were observed for prednisone, azathioprine, and mycophenolate relative to methotrexate.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Risk of systemic infections in adults with atopic dermatitis: A nationwide cohort study

Catherine Droitcourt et al.

Summary: The study found an increased risk of systemic infections among adults with hospital managed atopic dermatitis (AD), especially in terms of musculoskeletal, heart, respiratory tract, and skin infections.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial

J. I. Silverberg et al.

Summary: The study demonstrates that tralokinumab in combination with TCS is effective and well tolerated in patients with moderate-to-severe AD; high dose tralokinumab showed superior efficacy compared to placebo at 16 weeks. Patients who continued tralokinumab treatment at week 32 maintained response. The overall incidence of adverse events was similar across treatment groups.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)

A. Wollenberg et al.

Summary: Tralokinumab monotherapy was found to be superior to placebo at 16 weeks of treatment in two 52-week phase III trials, ECZTRA 1 and ECZTRA 2, and was well tolerated up to 52 weeks of treatment with sustained efficacy.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity scoreematched cohort study

Maria C. Schneeweiss et al.

Summary: The study found that patients with AD who initiated dupilumab had a higher risk of conjunctivitis within 6 months, but a lower risk of serious infections. Clinically meaningful increase in conjunctivitis needs to be managed in practice.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Allergy

Atopic eczema in adulthood and mortality: UK population-based cohort study, 1998-2016

Richard J. Silverwood et al.

Summary: The risk of death for adults with atopic eczema is influenced by the severity and activity of the eczema, with higher mortality risk seen in those with severe or active eczema. While the overall hazard for all-cause mortality is limited, there is a slightly increased risk for specific causes of death.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Dermatology

Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

Joseph F. Merola et al.

Summary: In adults with moderate-to-severe atopic dermatitis treated with tralokinumab 300 mg every 2 weeks, there were no negative effects on immune responses to tetanus, diphtheria, and meningococcal vaccines. The treatment was well tolerated when administered with the vaccines and had a safety profile similar to phase 3 trials.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Review Rheumatology

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Peter Nash et al.

Summary: The use of Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases has been extensively reviewed to provide guidance on efficacy and safety. A consensus statement was formed by an expert committee, evaluating 26 key points in six areas, with high levels of agreement and evidence-based recommendations. This consensus offers valuable insights for the practical management of JAKi in clinical practice.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Dermatology